|
1
|
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S and Vigneri R: Worldwide increasing incidence of
thyroid cancer: Update on epidemiology and risk factors. J Cancer
Epidemiol. 2013:9652122013.PubMed/NCBI
|
|
2
|
Goyal N, Setabutr D, Abdulghani J and
Goldenberg D: Molecular and genetic markers of follicular-cell
thyroid cancer: Etiology and diagnostic and therapeutic
opportunities. Adv Exp Med Biol. 779:309–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nikiforov YE: Molecular diagnostics of
thyroid tumors. Arch Pathol Lab Med. 135:569–577. 2011.PubMed/NCBI
|
|
4
|
Grogan RH, Mitmaker EJ and Clark OH: The
evolution of biomarkers in thyroid cancer-from mass screening to a
personalized biosignature. Cancers (Basel). 2:885–912. 2010.
View Article : Google Scholar
|
|
5
|
Cabanillas ME, Patel A, Danysh BP, Dadu R,
Kopetz S and Falchook G: BRAF inhibitors: Experience in thyroid
cancer and general review of toxicity. Horm Cancer. 6:21–36. 2015.
View Article : Google Scholar :
|
|
6
|
Kim KB, Cabanillas ME, Lazar AJ, Williams
MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI: Clinical
responses to vemurafenib in patients with metastatic papillary
thyroid cancer harboring BRAF(V600E) mutation. Thyroid.
23:1277–1283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li
Z, Wang S, Xiong Y, Guo H, He W, et al: Cytokeratin 19,
thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive
behavior of papillary thyroid carcinoma. Int J Clin Exp Med.
7:2304–2308. 2014.PubMed/NCBI
|
|
8
|
Flanagan JN, Pineda P, Knapp PE, De Las
Morenas A, Lee SL and Braverman LE: Expression of cytokeratin 19 in
the diagnosis of thyroid papillary carcinoma by quantitative
polymerase chain reaction. Endocr Pract. 14:168–174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krzeslak A, Gaj Z, Pomorski L and Lipinska
A: Expression of cytokeratin 19 in the cytosolic fraction of
thyroid lesions: ELISA and western blot analysis. Mol Med Rep.
1:565–569. 2008.PubMed/NCBI
|
|
10
|
Sumana BS, Shashidhar S and Shivarudrappa
AS: Galectin-3 immunohistochemical expression in thyroid neoplasms.
J Clin Diagn Res. 9:EC07–EC11. 2015.PubMed/NCBI
|
|
11
|
Bartolazzi A, Gasbarri A, Papotti M,
Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F,
Nardi F, et al Thyroid Cancer Study Group: Application of an
immunodiagnostic method for improving preoperative diagnosis of
nodular thyroid lesions. Lancet. 357:1644–1650. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Inohara H, Honjo Y, Yoshii T, Akahani S,
Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A and Kubo T:
Expression of galectin-3 in fine-needle aspirates as a diagnostic
marker differentiating benign from malignant thyroid neoplasms.
Cancer. 85:2475–2484. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gasbarri A, Martegani MP, Del Prete F,
Lucante T, Natali PG and Bartolazzi A: Galectin-3 and CD44v6
isoforms in the preoperative evaluation of thyroid nodules. J Clin
Oncol. 17:3494–3502. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carpi A, Rossi G, Coscio GD, Iervasi G,
Nicolini A, Carpi F, Mechanick JI and Bartolazzi A: Galectin-3
detection on large-needle aspiration biopsy improves preoperative
selection of thyroid nodules: A prospective cohort study. Ann Med.
42:70–78. 2010. View Article : Google Scholar
|
|
15
|
Liu Z, Yu P, Xiong Y, Zeng W, Li X,
Maiaiti Y, Wang S, Song H, Shi L, Liu C, et al: Significance of
CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid
carcinoma. Int J Clin Exp Med. 8:4369–4374. 2015.PubMed/NCBI
|
|
16
|
Mataraci EA, Ozgüven BY and Kabukçuoglu F:
Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic
and nonneoplastic thyroid lesions. Pol J Pathol. 63:58–64.
2012.PubMed/NCBI
|
|
17
|
Schmitt AC, Cohen C and Siddiqui MT:
Paired box gene 8, HBME-1, and cytokeratin 19 expression in
preoperative fine-needle aspiration of papillary thyroid carcinoma:
Diagnostic utility. Cancer Cytopathol. 118:196–202. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Niedziela M, Maceluch J and Korman E:
Galectin-3 is not an universal marker of malignancy in thyroid
nodular disease in children and adolescents. J Clin Endocrinol
Metab. 87:4411–4415. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mehrotra P, Okpokam A, Bouhaidar R,
Johnson SJ, Wilson JA, Davies BR and Lennard TWJ: Galectin-3 does
not reliably distinguish benign from malignant thyroid neoplasms.
Histopathology. 45:493–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mills LJ, Poller DN and Yiangou C:
Galectin-3 is not useful in thyroid FNA. Cytopathology. 16:132–138.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park YJ, Kwak SH, Kim DC, Kim H, Choe G,
Park DJ, Jang HC, Park SH, Cho BY and Park SY: Diagnostic value of
galectin-3, HBME-1, cytokeratin 19, high molecular weight
cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis
of thyroid nodules. J Korean Med Sci. 22:621–628. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X
and Zhu X: Diagnostic significance of CK19, RET, galectin-3 and
HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol.
63:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barroeta JE, Baloch ZW, Lal P, Pasha TL,
Zhang PJ and LiVolsi VA: Diagnostic value of differential
expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign
and malignant follicular-derived lesions of the thyroid: An
immunohistochemical tissue microarray analysis. Endocr Pathol.
17:225–234. 2006. View Article : Google Scholar
|
|
24
|
Hirabayashi J: Recent topics on galectins.
Trends Glycosci Glycotechnol. 9:1–180. 1997.
|
|
25
|
Kaltner H and Gabius HJ: A toolbox of
lectins for translating the sugar code: The galectin network in
phylogenesis and tumors. Histol Histopathol. 27:397–416.
2012.PubMed/NCBI
|
|
26
|
Cludts S, Decaestecker C, Mahillon V,
Chevalier D, Kaltner H, André S, Remmelink M, Leroy X, Gabius HJ
and Saussez S: Galectin-8 up-regulation during hypopharyngeal and
laryngeal tumor progression and comparison with galectin-1, -3 and
-7. Anticancer Res. 29:4933–4940. 2009.
|
|
27
|
Remmelink M, de Leval L, Decaestecker C,
Duray A, Crompot E, Sirtaine N, André S, Kaltner H, Leroy X, Gabius
HJ, et al: Quantitative immunohistochemical fingerprinting of
adhesion/growth-regulatory galectins in salivary gland tumours:
Divergent profiles with diagnostic potential. Histopathology.
58:543–556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dawson H, André S, Karamitopoulou E,
Zlobec I and Gabius HJ: The growing galectin network in colon
cancer and clinical relevance of cytoplasmic galectin-3 reactivity.
Anticancer Res. 33:3053–3059. 2013.PubMed/NCBI
|
|
29
|
Toegel S, Bieder D, André S, Kayser K,
Walzer SM, Hobusch G, Windhager R and Gabius HJ: Human
osteoarthritic knee cartilage: Fingerprinting of
adhesion/growth-regulatory galectins in vitro and in situ indicates
differential upregulation in severe degeneration. Histochem Cell
Biol. 142:373–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saussez S, Decaestecker C, Cludts S,
Ernoux P, Chevalier D, Smetana K Jr, André S, Leroy X and Gabius
HJ: Adhesion/growth-regulatory tissue lectin galectin-1 in relation
to angiogenesis/lymphocyte infiltration and prognostic relevance of
stromal up-regulation in laryngeal carcinomas. Anticancer Res.
29:59–65. 2009.PubMed/NCBI
|
|
31
|
Amano M, Eriksson H, Manning JC, Detjen
KM, André S, Nishimura S, Lehtiö J and Gabius HJ: Tumour suppressor
p16(INK4a) - anoikis-favouring decrease in N/O-glycan/cell surface
sialylation by down-regulation of enzymes in sialic acid
biosynthesis in tandem in a pancreatic carcinoma model. FEBS J.
279:4062–4080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smetana K Jr, André S, Kaltner H, Kopitz J
and Gabius HJ: Context-dependent multifunctionality of galectin-1:
A challenge for defining the lectin as therapeutic target. Expert
Opin Ther Targets. 17:379–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiariotti L, Berlingieri MT, Battaglia C,
Benvenuto G, Martelli ML, Salvatore P, Chiappetta G, Bruni CB and
Fusco A: Expression of galectin-1 in normal human thyroid gland and
in differentiated and poorly differentiated thyroid tumors. Int J
Cancer. 64:171–175. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu XC, el-Naggar AK and Lotan R:
Differential expression of galectin-1 and galectin-3 in thyroid
tumors. Potential diagnostic implications. Am J Pathol.
147:815–822. 1995.PubMed/NCBI
|
|
35
|
Salajegheh A, Dolan-Evans E, Sullivan E,
Irani S, Rahman MA, Vosgha H, Gopalan V, Smith RA and Lam AK: The
expression profiles of the galectin gene family in primary and
metastatic papillary thyroid carcinoma with particular emphasis on
galectin-1 and galectin-3 expression. Exp Mol Pathol. 96:212–218.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saussez S, Glinoer D, Chantrain G, Pattou
F, Carnaille B, André S, Gabius HJ and Laurent G: Serum galectin-1
and galectin-3 levels in benign and malignant nodular thyroid
disease. Thyroid. 18:705–712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaltner H, Seyrek K, Heck A, Sinowatz F
and Gabius HJ: Galectin-1 and galectin-3 in fetal development of
bovine respiratory and digestive tracts. Comparison of cell
type-specific expression profiles and subcellular localization.
Cell Tissue Res. 307:35–46. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
39
|
Kopitz J, Vértesy S, André S, Fiedler S,
Schnölzer M and Gabius HJ: Human chimera-type galectin-3: Defining
the critical tail length for high-affinity glycoprotein/cell
surface binding and functional competition with galectin-1 in
neuroblastoma cell growth regulation. Biochimie. 104:90–99. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
de Matos LL, Del Giglio AB, Matsubayashi
CO, de Lima Farah M, Del Giglio A and da Silva Pinhal MA:
Expression of CK-19, galectin-3 and HBME-1 in the differentiation
of thyroid lesions: Systematic review and diagnostic meta-analysis.
Diagn Pathol. 7:972012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dunđerović D, Lipkovski JM, Boričic I,
Soldatović I, Božic V, Cvejić D and Tatić S: Defining the value of
CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell
derived lesions of thyroid with systematic review of literature.
Diagn Pathol. 10:1962015. View Article : Google Scholar
|
|
42
|
Toegel S, Weinmann D, André S, Walzer SM,
Bilban M, Schmidt S, Chiari C, Windhager R, Krall C, Bennani-Baiti
IM, et al: Galectin-1 couples glycobiology to inflammation in
osteoarthritis through the activation of an NF-κB-regulated gene
network. J Immunol. 196:1910–1921. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu X, Wang K, Zhang K, Xu F, Yin Y, Zhu L
and Zhou F: Galectin-1 knockdown in carcinoma-associated
fibroblasts inhibits migration and invasion of human MDA-MB-231
breast cancer cells by modulating MMP-9 expression. Acta Biochim
Biophys Sin (Shanghai). 48:462–467. 2016. View Article : Google Scholar
|
|
44
|
Saussez S, Cludts S, Capouillez A,
Mortuaire G, Smetana K Jr, Kaltner H, André S, Leroy X, Gabius HJ
and Decaestecker C: Identification of matrix metalloproteinase-9 as
an independent prognostic marker in laryngeal and hypopharyngeal
cancer with opposite correlations to adhesion/growth-regulatory
galectins-1 and -7. Int J Oncol. 34:433–439. 2009.PubMed/NCBI
|
|
45
|
Nucera C, Nehs MA, Mekel M, Zhang X, Hodin
R, Lawler J, Nose V and Parangi S: A novel orthotopic mouse model
of human anaplastic thyroid carcinoma. Thyroid. 19:1077–1084. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sewell W, Reeb A and Lin RY: An orthotopic
mouse model of anaplastic thyroid carcinoma. J Vis Exp. 74:2013.
View Article : Google Scholar
|
|
47
|
Antonello ZA and Nucera C: Orthotopic
mouse models for the preclinical and translational study of
targeted therapies against metastatic human thyroid carcinoma with
BRAF(V600E) or wild-type BRAF. Oncogene. 33:5397–5404. 2014.
View Article : Google Scholar
|
|
48
|
Camby I, Belot N, Lefranc F, Sadeghi N, de
Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, et
al: Galectin-1 modulates human glioblastoma cell migration into the
brain through modifications to the actin cytoskeleton and levels of
expression of small GTPases. J Neuropathol Exp Neurol. 61:585–596.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Martínez-Bosch N, Fernández-Barrena MG,
Moreno M, Ortiz-Zapater E, Munné-Collado J, Iglesias M, André S,
Gabius HJ, Hwang RF, Poirier F, et al: Galectin-1 drives pancreatic
carcinogenesis through stroma remodeling and Hedgehog signaling
activation. Cancer Res. 74:3512–3524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Solís D, Bovin NV, Davis AP,
Jiménez-Barbero J, Romero A, Roy R, Smetana K Jr and Gabius HJ: A
guide into glycosciences: How chemistry, biochemistry and biology
cooperate to crack the sugar code. Biochim Biophys Acta.
1850:186–235. 2015. View Article : Google Scholar
|
